Journal
JOURNAL OF LIPOSOME RESEARCH
Volume 31, Issue 1, Pages 1-10Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/08982104.2019.1682604
Keywords
Liposomes; curcumin; doxorubicin; pharmacokinetics; biodistribution
Funding
- Romanian National Authority for Scientific Research and Innovation, CNCS-UEFISCDI [PN-II-RU-TE-2014-4-0220]
Ask authors/readers for more resources
The study aimed to investigate the pharmacokinetic profile, tissue distribution, and adverse effects of long-circulating liposomes containing curcumin and doxorubicin. It demonstrated that the liposomal association of curcumin and doxorubicin effectively improved the pharmacokinetics and biodistribution of doxorubicin, limiting its side effects through curcumin-dependent antioxidant effects.
The goal of the current study was to investigate the pharmacokinetic profile, tissue distribution and adverse effects of long-circulating liposomes (LCL) with curcumin (CURC) and doxorubicin (DOX), in order to provide further evidence for previously demonstrated enhanced antitumor efficacy in colon cancer models. The pharmacokinetic studies were carried out in healthy rats, following the i.v. injection of a single dose of LCL-CURC-DOX (1 mg/kg DOX). For the tissue distribution study, DOX concentration in tumours, heart and liver were measured after the administration of two i.v. doses of LCL-CURC-DOX (2.5 mg/kg DOX and 5 mg/kg CURC) to Balb/c mice bearing C26 colon tumours. Markers of murine cardiac and hepatic oxidative status were determined to provide additional insights into the benefit of co-encapsulating CURC and DOX in LCL over DOX-induced adverse effects in these organs. The current study demonstrated that the liposomal association of CURC and DOX effectively improved the pharmacokinetics and biodistribution of DOX, limiting its side effects, via CURC-dependent antioxidant effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available